kr450.00
4.26%
Copenhagen, Oct 03, 04:59 pm CET
ISIN
DK0062266474
Symbol
GUBRA

Gubra A/S Stock price

kr450.00
+48.40 12.05% 1M
+82.40 22.42% 6M
-101.40 18.39% YTD
+34.68 8.35% 1Y
+352.80 362.96% 3Y
+352.80 362.96% 5Y
+352.80 362.96% 10Y
+352.80 362.96% 20Y
Copenhagen, Closing price Fri, Oct 03 2025
+18.40 4.26%

Key metrics

Basic
Market capitalization
kr7.1b
Enterprise Value
kr4.4b
Net debt
positive
Cash
kr2.7b
Shares outstanding
16.3m
Valuation (TTM | estimate)
P/E
4.1 | 3.9
P/S
2.6 | 20.4
EV/Sales
1.6 | 12.8
EV/FCF
1.9
P/B
5.8
Financial Health
Equity Ratio
73.6%
Return on Equity
-8.1%
ROCE
174.7%
ROIC
-127.6%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
kr2.7b | kr345.4m
EBITDA
- | kr1.8b
EBIT
kr2.3b | kr1.8b
Net Income
kr1.8b | kr1.9b
Free Cash Flow
kr2.3b
Growth (TTM | estimate)
Revenue
1,104.0% | 30.0%
EBITDA
- | 4,584.8%
EBIT
4,536.1% | 3,665.3%
Net Income
3,977.1% | 5,316.7%
Free Cash Flow
4,626.5%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
- | 521.8%
EBIT
83.8%
Net
66.9% | 551.3%
Free Cash Flow
84.5%
More
EPS
kr109.6
FCF per Share
kr139.4
Short interest
-
Employees
260
Rev per Employee
kr1.0m
Show more

Is Gubra A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

Gubra A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Gubra A/S forecast:

10x Buy
83%
2x Hold
17%

Analyst Opinions

12 Analysts have issued a Gubra A/S forecast:

Buy
83%
Hold
17%

Financial data from Gubra A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,695 2,695
1,104% 1,104%
100%
- Direct Costs 96 96
4% 4%
4%
2,541 2,541
1,833% 1,833%
94%
- Selling and Administrative Expenses 130 130
52% 52%
5%
- Research and Development Expense 210 210
116% 116%
8%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 2,259 2,259
4,536% 4,536%
84%
Net Profit 1,804 1,804
3,977% 3,977%
67%

In millions DKK.

Don't miss a Thing! We will send you all news about Gubra A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Gubra ApS operates as biotechnology company. It engages in the business of pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. The company operates through two business segments: CRO Services and Discovery & Partnerships. The CRO Services segment provides specialized pre-clinical contract research and development services for the pharmaceutical and biotechnology industry. The Discovery & Partnerships segment involves in discovery, design and development of peptide-based drug candidates with the aim of entering partnerships with pharmaceutical or biotechnology companies. Gubra was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Mr. Blou
Employees 260
Founded 2008
Website www.gubra.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today